Anika Therapeutics, Inc. Additional Paid in Capital, Common Stock
Anika Therapeutics, Inc. (ANIK) had Additional Paid in Capital, Common Stock of $83.44 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-07-29
- 2026-06-30: Additional Paid in Capital, Common Stock $83.44M.
- 2026-03-31: Additional Paid in Capital, Common Stock $83.35M.
- 2025-12-31: Additional Paid in Capital, Common Stock $87.50M.
- 2025-09-30: Additional Paid in Capital, Common Stock $91.11M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $83.44M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $83.35M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $87.50M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $91.11M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $89.46M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $87.56M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $88.96M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $91.89M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $93.16M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $91.17M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $90.01M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $85.85M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $82.40M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $83.24M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $81.14M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $76.66M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $72.85M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $68.80M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $67.08M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $63.86M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $60.70M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $57.28M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $55.35M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $52.51M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $50.61M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $48.36M 10-Q · filed 2020-05-22 | |
| 2019-12-31 | $48.71M 10-K/A · filed 2021-04-26 | |
| 2019-09-30 | $46.48M 10-Q · filed 2019-10-28 | |
| 2019-06-30 | $24.33M 10-Q · filed 2019-07-26 | |
| 2019-03-31 | $52.03M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | $50.76M 10-K · filed 2020-03-06 | |
| 2018-09-30 | $49.84M 10-Q · filed 2018-10-26 | |
| 2018-06-30 | $48.66M 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $74.96M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $68.62M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $66.75M 10-Q · filed 2017-10-27 | |
| 2017-06-30 | $65.17M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $63.72M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $61.73M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $60.37M 10-Q · filed 2016-11-01 | |
| 2016-06-30 | $59.51M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $58.54M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $81.69M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $81.05M 10-Q · filed 2015-11-03 | |
| 2015-06-30 | $80.51M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $79.99M 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $77.54M 10-K · filed 2016-03-10 | $77.54M 10-K · filed 2015-03-13 |
| 2014-09-30 | $76.06M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $73.25M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $76.53M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $70.61M 10-K · filed 2015-03-13 | |
| 2013-09-30 | $70.28M 10-Q · filed 2013-11-05 | |
| 2012-12-31 | $65.43M 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |